Sequence: (R-Ahx-R)3-IdKILFQN-dRRMKWHKBC
| Experiment Id | EXP001332 |
|---|---|
| Paper | Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon ski |
| Peptide | Pip2a–PNA705 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | covalent peptide–PNA conjugate (disulfide or thioether linkage) |
| Formulation Components | HeLa pLuc705 splice-correction assay; conjugates incubated 4 h in OptiMEM then 20 h in complete medium; readouts: luciferase upregulation and RT-PCR splice correction. PNA cargo: Cys-Lys-CCTCTTACCTCAGTTACA-Lys-amide (PNA705, 18-mer). Serum-stabilized Pip peptide (candidate for in vivo). |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa pLuc705 cells |
| Animal Model | |
| Administration Route | |
| Output Type | EC50 (RT-PCR splice correction, µM) |
| Output Value | 0.79 |
| Output Units | |
| Output Notes | Supplementary Table 1 lists Pip2a–PNA705 EC50 = 0.79 ± 0.13 µM; predominantly stable 1 h in 20% mouse serum. |
| Toxicity Notes | |
| Curation Notes |